ADAGENE ANNOUNCES FOUR POSTER PRESENTATIONS ON ROBUST PRECLINICAL PIPELINE OF ANTIBODY-BASED THERAPEUTICS AT UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

 - New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company’s AI-powered platform -

- SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, designed to further enhance efficacy with secured safety -

- Data show safe, powerful and durable immunotherapy for solid tumors can be achieved through combination of the fundamental mechanisms and pathways across the cancer immunity cycle -

SAN DIEGO and SUZHOU, China, March 9 (Bernama-GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022. The full abstracts are available on the AACR meeting website.

At AACR, presentations will include preclinical results showing the potential best-in-class profiles for three differentiated preclinical product candidates in IND-enabling studies: ADG138, ADG206 and ADG153. The fourth presentation introduces a new capability for the company’s proprietary bispecific T-cell engagers (TCEs) with CD28.

Details for the poster presentations include:

· Title: ADG138, A Novel HER2×CD3 POWERbody™ Integrating Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and On-Target Off-Tumor Toxicity for Single Agent and Combination Therapies in HER2-Expressing Solid Tumors

Date: Tuesday April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 37
Abstract Number: 2869

· Title: ADG206, an anti-CD137 agonistic POWERbody^TM with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single agent and combinational cancer immunotherapy

Date: Tuesday, April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 37
Abstract Number: 2868

·  Title: Tumor-targeted CD28 bispecific POWERbody^TM for safe and synergistic T cell-mediated immunotherapy

Date: Tuesday, April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 38
Abstract Number: 2888 

http://mrem.bernama.com/viewsm.php?idm=42609